

Our ref: IG/FOI/FOI.124.26

26 March 2026

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information, which was received on 20 March 2026, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) partly holds the information that you require. For ease of reference your request is set out below and the Health Board's response follows each question individually.

Your Freedom of Information (FOI) Request and Powys Response (Bold):

I am writing to you under the Freedom of Information Act to request the following information: I am conducting analysis on the diagnosis of Alzheimer's Disease and would be grateful if you could answer the questions below for all relevant activity within the Health Board.

1. Where, if at all, does the Health Board carry out lumbar punctures (cerebrospinal fluid) for diagnosing patients with Alzheimer's Disease?

	Yes / No
Lumbar punctures carried out within the Trust itself	No
Lumbar punctures referred elsewhere and carried out external to the Trust	No
Trust does not carry out lumbar punctures to diagnose Alzheimer's Disease	Yes

2. Please provide a list of the full names of other Trusts or other organisations to which the Trust refers patients for lumbar puncture procedures in the diagnosis of Alzheimer's Disease.

Full name of organisation(s)
Not applicable.

3. How many lumbar puncture procedures to test for Alzheimer's Disease were performed in the last three-month period for which data are available?

	Number of procedures
Number of lumbar punctures	Not applicable

4. Where, if at all, does the Health Board carry out Blood Biomarker (BBM) tests for diagnosing NHS patients with Alzheimer's Disease?

	Yes / No
Pathology laboratory within the Trust	No
Pathology laboratory external to the Trust	No
Trust does not test for BBMs to diagnose Alzheimer's Disease	Yes

5. Please provide a list of the full names of other Trusts or other organisations, to which the Trust refers Blood Biomarker tests for the diagnosis of Alzheimer's Disease for NHS patients.

Full name of Trust or organisation(s)
Not applicable

6. Please provide the number of BBM tests for Alzheimer's Disease conducted over the last three-months, regardless of whether they were carried out within your organisation or sent to an external pathology laboratory.

	Number of tests TOTAL	Number of tests NHS patients	Number of tests Private Sector
Number of Blood Biomarker tests	Not applicable		

7. Which of the following biomarker tests were used to detect Alzheimer's Disease?

	Yes / No
pTau181 immunoassay tests	No
pTau217 immunoassay tests	No

8. Please provide a list of the full names of other Trusts or other organisations, to which the Trust refers samples for pTau181 and pTau217 immunoassay testing for Alzheimer's Disease?

Full name of Trust or organisation(s)
Not applicable.

9. How many pTau181 immunoassay tests were conducted to test for Alzheimer's Disease in the last three-months?

	Number of tests TOTAL	Number of tests NHS patients	Number of tests Private Sector
Number of pTau181 tests	Not applicable		

10. Is pTau181 testing for Alzheimer's Disease linked to, or conducted in conjunction with, clinical trials?

	Yes / No
pTau181 Testing associated with clinical trial activity	No

11. How many pTau181 immunoassay tests were conducted for Alzheimer's Disease as part of a clinical trial?

Number of pTau181 tests	Not applicable.
-------------------------	------------------------

12. How many pTau217 immunoassay tests were conducted to test for Alzheimer's Disease in the last three-months?

	Number of tests TOTAL	Number of tests NHS patients	Number of tests Private Sector
Number of pTau217 tests	Not applicable.		

13. Is pTau217 testing for Alzheimer's Disease linked to, or conducted in conjunction with, clinical trials?

	Yes / No
pTau217 Testing associated with clinical trial activity	Not applicable.

14. How many pTau217 immunoassay tests were conducted for Alzheimer's Disease as part of a clinical trial?

Number of pTau217 tests	Not applicable.
-------------------------	------------------------

15. Does your organisation participate in any of the following clinical trials?

	Yes / No
READ-OUT	No
ADAPT	No
Other(s) please specify below:	Yes
Sandbox Clinical trials	

16. Which of the following metrics are used by the Trust to measure Blood Biomarker in the diagnosis of Alzheimer's Disease?

	Yes / No
Number of tests	Not applicable.
Number of kits	Not applicable.
Number of runs	Not applicable.

Number of units	Not applicable.
Number of patients	Not applicable.

If you have queries or any concerns, contact details are given at the top of the letter. Please remember to quote the reference number above in any future communications. If you are dissatisfied with the handling or response to your request and wish to ask for a review of this, please contact us and we will arrange for this to be done.

Further information is available from the Information Commissioner's Office who can be contacted at:

Address: Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH.

Telephone: 0330 414 6421

Complaints Portal: www.ico.org.uk/foicomplaints

Web site: <https://ico.org.uk/>

Re-use of Public Sector Information

All information supplied by the Health Board in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2015.

Under the terms of the Regulations, the Health Board will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however, the Health Board reserves the right, in certain circumstances to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information including a sample license terms and fees can be found at Open Government Licence.

Yours sincerely



Louisa Kerr

Assistant Director for Mental Health and Learning Disabilities

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.